Participant 2: MERCK
Merck KGaA, Institute of Toxicology, Darmstadt, Germany
Participant leader: Dr. Stefan O. Mueller
Relevant experience and laboratory resources:
Merck KGaA is the lead organisation in the world-wide Merck group of chemical and pharmaceutical companies. The Merck Group has a long and successful history in the development and manufacture of chemical and pharmaceutical materials resulting in a product range containing more than 15,000 items. The MERCK group has strong commitment to research and development with one tenth of its work force engaged in this field. The Institute of Toxicology at Merck KGaA in Darmstadt has the global function of drug and chemical safety assessment for the Merck group. To ensure that up-to-date methods are applied, to constantly improve the safety of products, and to educate young toxicologists, toxicological research and method development is constantly done in parallel to the toxicological safety assessment of products. It is participating furthermore in projects funded by the German government (BMBF) as well as the EC (InnoMed/PredTox) and spends more than 10% of its budget for research activities (more than 1 million Euro per year). The Institute is fully equipped with state-of-the-art animal facilities as well as molecular and cellular biology technologies. This group has an extensive experience and knowledge in the field of generation of genetically modified cell lines, primary cell cultures as well as biotransformation. In addition the Molecular Toxicology group at Merck is dedicated to develop, modify and employ molecular technologies as tools for human risk assessment.
Principal staff involved:
Dr. S. O. Mueller (M) is a board certified toxicologist of the German Toxicology Society (EUROTOX) and holds a professorship in toxicology at the Institute of Applied Biological Sciences at the Technical University Karlsruhe, Germany. He has published more than 25 peer-reviewed articles and serves as reviewer for several toxicological and molecular biology journals. He is senior toxicologist at Merck and head of the laboratory Cellular Systems at the Institute of Toxicology of Merck KGaA. The focus of his research activities for the past 9 years was on alternative methods in particular tissue and cell culture models that mimic toxicological relevant target organs such as the liver. He has also a broad experience in international project work. His activities will be funded 100% by Merck.
Birthe Lauer (F)
Dr. P. Hewitt (M) is a UK registered board certified toxicologist (EUROTOX) and has a PhD from Imperial College, London. He has published more than 20 articles in peer-reviewed journals and books. He has spent 9 years establishing the Molecular Toxicology group at Merck KGaA and is currently head of the Toxicogenomics lab in the Institute of Toxicology. The major goals being to establish early predictive models based on gene expression and the elucidation of toxicological mechanisms. He is also responsible for the implementation of metabolomics into toxicological research. He has also experience in international project work. His activities will be partly funded by Merck.
M. Kling (F; 25%), technician, will work on liver cell culture and C. Klement (F; 25%) will perform the experimental part of the Affymetrix expression analysis (both technicians will be partly funded by Merck).
Role of the participant in the project and main tasks:
The participant will contribute to the general management of the project as deputy coordinator, is responsible for coordinating WP2.1, WP4 and WP6 and will perform work in WP2, 4 and 6.